⌘K
Loading ticker…
As of 2026-08-24, Artiva Biotherapeutics, Inc. Common Stock (ARTV) has a 3-month relative strength percentile of 93 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 90. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.5%, relative volume 0.92×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
ARTV is in a stage 2 uptrend, week 6. Currently in a 87-day base; basing ADR 9.9% (broad 10.0%). VCP detected: no. RS line below base-start high. Distance from 50d / 200d: 13.1% / 63.4%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
ARTV is held by 2 ETFs as of Apr 2026. Top owner: DCOR at 0.00% weight, $31K notional.
Held by 6 ETFs · $2M across latest filings · largest weight 0.22% (SURI).
Top 2 by value, from SEC N-PORT-P filings dated Apr 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| DCOR | 0.00% | $31K | — |
| DFASDimensional U.S. Small Cap ETF | 0.00% | $7K | new |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Related searches
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARTV Jan avg: -29.46% median: -29.46% win: 0% σ: 28.48% n: 2 2024-07-22 → 2026-07-31 | ARTV Feb avg: 15.65% median: 15.65% win: 50% σ: 48.03% n: 2 2024-07-22 → 2026-07-31 | ARTV Mar avg: -8.53% median: -8.53% win: 50% σ: 27.13% n: 2 2024-07-22 → 2026-07-31 | ARTV Apr avg: 19.34% median: 19.34% win: 50% σ: 56.10% n: 2 2024-07-22 → 2026-07-31 | ARTV May avg: -20.90% median: -20.90% win: 0% σ: 2.34% n: 2 2024-07-22 → 2026-07-31 | ARTV Jun avg: 0.28% median: 0.28% win: 50% σ: 31.17% n: 2 2024-07-22 → 2026-07-31 | ARTV Jul avg: 33.71% median: 4.12% win: 67% σ: 56.34% n: 3 2024-07-22 → 2026-07-31 | ARTV Aug avg: 1.40% median: 1.40% win: 50% σ: 5.09% n: 2 2024-07-22 → 2026-07-31 (current) | ARTV Sep avg: 12.50% median: 12.50% win: 50% σ: 30.24% n: 2 2024-07-22 → 2026-07-31 | ARTV Oct avg: 5.46% median: 5.46% win: 50% σ: 56.33% n: 2 2024-07-22 → 2026-07-31 | ARTV Nov avg: 8.10% median: 8.10% win: 50% σ: 25.36% n: 2 2024-07-22 → 2026-07-31 | ARTV Dec avg: -3.52% median: -3.52% win: 50% σ: 24.91% n: 2 2024-07-22 → 2026-07-31 |